Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.


Journal

Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 04 04 2024
revised: 25 05 2024
accepted: 12 06 2024
medline: 30 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: ppublish

Résumé

The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer. However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies. This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field. Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis. In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.

Identifiants

pubmed: 39473401
pii: S2768-6701(24)01365-0
doi: 10.31083/j.fbl2910349
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

349

Informations de copyright

© 2024 The Author(s). Published by IMR Press.

Auteurs

Namdev Dhas (N)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Ritu Kudarha (R)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Sanjay Kulkarni (S)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Soji Soman (S)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Prerana D Navti (PD)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Jahnavi Kulkarni (J)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Amrita Arup Roy (AA)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Viola Colaco (V)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Ruchira Raychaudhuri (R)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Ashutosh Gupta (A)

Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Chandrakantsing Pardeshi (C)

Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, 425405 Shirpur, Maharashtra, India.

Dipak Bari (D)

Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, 425405 Shirpur, Maharashtra, India.

Ruchi Tiwari (R)

PSIT-Pranveer Singh Institute of Technology (Pharmacy), 209305 Kanpur, Uttar Pradesh, India.

Jayvadan Patel (J)

Faculty of Pharmacy, Sankalchand Patel University, 384315 Visnagar, Gujurat, India.

Sudheer Moorkoth (S)

Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Srinivas Mutalik (S)

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH